<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7128742/results/search/test_trace/results.xml">
  <result pre="we mean using HCQ for post-exposure of people with close" exact="contact" post="with patients with positive COVID19 rtPCR, including home and"/>
  <result pre="use of HCQ at doses matching that of the standard" exact="treatment" post="of Systemic Lupus erythematous, which has proven safety and"/>
  <result pre="not uniformly, and other known public health measures such as" exact="contact" post="tracing are also variably implemented. Clinical trials are underway"/>
  <result pre="uniformly, and other known public health measures such as contact" exact="tracing" post="are also variably implemented. Clinical trials are underway using"/>
  <result pre="initial studies are observational and not controlled studies. Thus, documented" exact="treatment" post="is still lacking. In spite of the paucity of"/>
  <result pre="effect of chloroquine on COVID-19, the absence of an effective" exact="treatment" post="so far, the untimely publicity given to the potential"/>
  <result pre="release of the drug for its compassionate use in the" exact="treatment" post="of severe cases. Meanwhile, the development of a safe"/>
  <result pre="adequately addressed is the pharmacological control of virus replication in" exact="contact" post="cases before individuals show symptoms. Use of drugs has"/>
  <result pre="can prophylactic doses of hydroxychloroquine decrease the risk of clinical" exact="infection" post="in documented exposed people? Considering the ongoing world tragedy,"/>
  <result pre="as post-exposure drug for exposed people, meaning people with close" exact="contact" post="with positive tested patients, including home and medical caregivers."/>
  <result pre="treating hospitalized patients with symptomatic COVID-19, are highly susceptible to" exact="infection" post="and may represent a second wave of extreme importance"/>
  <result pre="Those highly exposed people should be protected. In that case," exact="social distancing" post="measures do not apply. In the absence of a"/>
  <result pre="or not they have been tested for SARS-CoV-2, in close" exact="contact" post="with symptomatic patients positive for SARS-CoV-2 and to start"/>
  <result pre="use of the HCQ to match that of the standard" exact="treatment" post="of Systemic Lupus erythematous which has proven safety and"/>
  <result pre="of the post-exposure regimen should last as long as the" exact="contact" post="with a positive patient last or in case of"/>
  <result pre="synthesized by Hans Andersag in 1934, and proven by military" exact="testing" post="during World War II as a safe antimalarial used"/>
  <result pre="(HCQ), has immunomodulatory properties; leading to its use in the" exact="treatment" post="of autoimmune diseases such as Lupus and rheumatoid arthritis"/>
  <result pre="oral, administration [30]. The risk of retinopathy associated with hydroxychloroquine" exact="treatment" post="has been well documented for decades. It was recently"/>
  <result pre="well documented for decades. It was recently shown that the" exact="prevalence" post="of retinopathy ranged from 5.2 to 7.5% in patients"/>
  <result pre="this drug regimen. However, we recommend ECG before initiation of" exact="treatment" post="in case of cardiac antecedents; but this should not"/>
  <result pre="may lead to hindering fusion of viral particles, when chloroquine" exact="treatment" post="was used for different emerging or non-emerging virus over"/>
  <result pre="the cytokine storm [42]. 5 Conclusion Non-pharmaceutical measures such as" exact="social distancing," post="school closure and teleworking (Di Domenico et al. Expected"/>
  <result pre="employ. Early HCQ administration to all people at risk of" exact="infection" post="from close contact with a positive patient is one"/>
  <result pre="administration to all people at risk of infection from close" exact="contact" post="with a positive patient is one of the most"/>
  <result pre="a recommendation to examine the effect of hydroxychloroquine in preventing" exact="infection" post="and progressionJ Antimicrob Chemother.20 mars 202010.1093/jac/dkaa114 2FanouriakisA.KostopoulouM.CheemaK.AndersH.-J.AringerM.BajemaI.2019 Update of"/>
  <result pre="Dis. Sept1192011653654 12VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J.222 août 20056916115318 13KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.Antiviral activity of"/>
  <result pre="20056916115318 13KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.Antiviral activity of chloroquine against human coronavirus OC43" exact="infection" post="in newborn miceAntimicrob Agents Chemother. Août538200934163421 14KumarM.TopnoR.K.DikhitM.R.Bhawana null, Sahoo"/>
  <result pre="for mouse hepatitis virus, strain JHMVirology. Mai19411993185191 24YoungentobS.L.SchwobJ.E.SahaS.ManglapusG.JubeltB.Functional consequences following" exact="infection" post="of the olfactory system by intranasal infusion of the"/>
  <result pre="optimization of chloroquine by pharmacokinetic modeling during pregnancy for the" exact="treatment" post="of Zika virus infectionJ Pharm Sci. Janv10812019661673 28CollinsK.P.JacksonK.M.GustafsonD.L.Hydroxychloroquine: a"/>
  <result pre="acidification by chloroquine analogs as a promising strategy for the" exact="treatment" post="of emerging viral diseasesPharmacol. Res. Perspect.512017e00293 34HuT.Y.FriemanM.WolframJ.Insights from nanomedicine"/>
  <result pre="(MHV-3)Virology. Mars2831966355362 36TakanoT.KatohY.DokiT.HohdatsuT.Effect of chloroquine on feline infectious peritonitis virus" exact="infection" post="in vitro and in vivoAntiviral Res. Août9922013100107 37YanY.ZouZ.SunY.LiX.XuK.-F.WeiY.Anti-malaria drug"/>
  <result pre="is highly effective in treating avian influenza a H5N1 virus" exact="infection" post="in an animal modelCell Res. Févr2322013300302 38SavarinoA.LuciaM.B.RastrelliE.RutellaS.GolottaC.MorraE.Anti-HIV effects of"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov.620201632194981"/>
 </snippets>
</snippetsTree>
